Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-03-06
2009-06-02
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S025000, C514S033000, C514S035000
Reexamination Certificate
active
07541342
ABSTRACT:
Compounds for the inducing apoptosis in cancer cells are described. The described compounds induce the translocation of protein kinase C-δ to the mitochondria and the phosphorylation of mitochondrial phospholipid scramblase 3. The compounds also provide cardioprotection through the translocation and activation of protein kinase C-ε in cardiomyocytes, thereby inhibiting apoptosis in carciomyocytes.
REFERENCES:
patent: 4610977 (1986-09-01), Israel et al.
patent: 6677309 (2004-01-01), Taatjes et al.
Barrett et al. Molecular Cancer Therapeutics (2002), vol. 1, pp. 469-481.
Overmoyer Journal of Clinical Oncology (2003), vol. 21, pp. 580-582.
Campos et al. Blood (1993), vol. 81, pp. 3091-3096.
Kantarjian et al. The New England Journal of Medicine (2002), vol. 346, pp. 645-652.
Notification Concerning Transmittal Of International Preliminary Report on Patentability (Chapter I of the Patent Cooperation Treaty) corresponding to PCT Application No. PCT/US2006/007853 dated.
International Search Report and Written Opinion of the International Searching Authority corresponding to PCT application No. PCT/US06/07853 dated Jun. 29, 2006.
Bachur et al., “Anthracycline Antibiotic Blockade of SV40 T Antigen Helicase Action”,Biochemical Pharmacology, 55: 1025-1034, 1998.
Esteva et al., “Chemotherapy of Metastic Breast Cancer: What to Expect in 2001 and Beyond,” The Oncologist, vol. 6, pp. 133-146 (2001).
Grazette et al., “Inhibition of ErbB2 Causes Mitochondrial Dysfunction in Cardiomyocytes,” Journal of the American College of Cardiology, vol. 44, No. 11 (2004).
He et al., “N-Benzyladriamycin-14-Valerate (AD 198) Induces Apoptosis through Protein Kinase C-δ-Induced Phosphorylation of Phospholipid Scramblase 3,” Cancer Res., vol. 65, No. 21, pp. 10016-10023 (Nov. 1, 2005).
Liu et al., “Protein Kinase C-δ and Its Downstream Effectors as Potential Targets for Cancer Therapy,” Cancer Therapy, vol. 1, pp. 275-281 (2003).
Roaten et al., “Interaction of the Novel Anthracycline Antitumor Agent N-Benzyladriamycin-14-valerate with the C1-Regulatory Domain of Protein Kinase C: Structural Requirements, Isoform Specificity, and Correlation with Drug Cytotoxicity,” Molecular Cancer Therapeutics, vol. 1, pp. 483-492 (May 2002).
Roaten et al., “Molecular Models of N-Benzyladriamycin-14-valerate (AD 198) in Complex with the Phorbol Ester-Binding C1b Domain of Protein Kinase C-δ,” J. Med. Chem., vol. 44, pp. 1028-1034 (2001).
Slamon et al., “Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer that Overexpresses HER2,” The New England Journal of Medicine, vol. 344, No. 11, pp. 783-792 (Mar. 15, 2001).
Barrett et al., “Novel Extranuclear-targeted Anthracyclines Override the Antiapoptotic Functions of Bcl-2 and Target Protein Kinase C Pathways to Induce Apoptosis”, Molecular Cancer Therapeutics, vol. 1, pp. 469-481 (May 2002).
Lothstein et al., “Cytotoxicity and Intracellular Biotransformation of N-Benzyladriamycin-14-Valerate (AD 198) Are Modulated by Changes in 14-O-acyl Chain Length”, Anti-Cancer Drugs, vol. 9, pp. 58-66 (1998).
Hofmann Polly A.
Israel Mervyn
Lothstein Leonard
Sweatman Trevor
Jenkins Wilson Taylor & Hunt, P.A.
Lewis Patrick T
University of Tennessee Research Foundation
LandOfFree
Use of PKC-activating compounds as cardioprotectants and as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of PKC-activating compounds as cardioprotectants and as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of PKC-activating compounds as cardioprotectants and as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4105840